Fractyl Health (NASDAQ:GUTS) Director Ajay Royan Buys 23,000 Shares

Fractyl Health, Inc. (NASDAQ:GUTS) Director Ajay Royan bought 23,000 shares of the company’s stock in a transaction dated Friday, June 12th. The stock was purchased at an average price of $0.85 per share, with a total value of $19,550.00. Following the completion of the transaction, the director directly owned 40,901 shares in the company, valued at approximately $34,765.85. This represents a 128.48% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Fractyl Health Price Performance

Shares of NASDAQ:GUTS opened at $0.85 on Tuesday. The firm has a 50 day moving average of $0.70 and a 200-day moving average of $1.06. The stock has a market capitalization of $134.85 million, a PE ratio of -0.66 and a beta of 2.34. The company has a current ratio of 4.28, a quick ratio of 4.28 and a debt-to-equity ratio of 1.41. Fractyl Health, Inc. has a 12 month low of $0.38 and a 12 month high of $2.45.

Fractyl Health (NASDAQ:GUTS) last issued its earnings results on Tuesday, May 12th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.17) by $0.23. On average, equities research analysts predict that Fractyl Health, Inc. will post -0.6 EPS for the current fiscal year.

Institutional Investors Weigh In On Fractyl Health

Several hedge funds have recently added to or reduced their stakes in GUTS. FNY Investment Advisers LLC acquired a new stake in Fractyl Health during the 3rd quarter worth approximately $31,000. Jane Street Group LLC acquired a new stake in Fractyl Health during the 2nd quarter worth approximately $31,000. Accredited Investors Inc. acquired a new stake in Fractyl Health during the 1st quarter worth approximately $46,000. Scientech Research LLC acquired a new stake in Fractyl Health during the 3rd quarter worth approximately $49,000. Finally, Prelude Capital Management LLC acquired a new stake in Fractyl Health during the 3rd quarter worth approximately $55,000.

Analysts Set New Price Targets

Several brokerages recently issued reports on GUTS. Wall Street Zen raised shares of Fractyl Health from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Fractyl Health in a report on Tuesday, May 12th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of Fractyl Health in a report on Thursday, June 4th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $8.00 price target on shares of Fractyl Health in a report on Thursday, March 26th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Fractyl Health has an average rating of “Hold” and a consensus price target of $5.40.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.